Citations

Mayo Clinic

Showing 10 of 108551 citations.

Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Kim, George P., Wang, Yulei , Scales, Suzie J. , Samineni, Divya , Brunstein, Flávia, Choi, YounJeong, Maslyar, Daniel, Colón‐Otero, Gerardo , McWilliams, Robert R. , Borad, Mitesh J. , Lieu, Christopher H. , de Vries, Elisabeth G E

Molecular Cancer Therapeutics | January 29, 2016 | Volume: 15 | Issue: 3 | Pages: 439-447

10.1158/1535-7163.mct-15-0693 | PMID 26823490 Get It

Abstract DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2–2.8 mg/kg; q3w) or weekly (0.8–1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventy-one patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n = 54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n = 17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer. Mol Cancer Ther; 15(3); 439–47. ©2016 AACR.
Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells
Bell, Michael P., Pavelko, Kevin D. , Pavelko, Kevin D

Molecular Cancer Therapeutics | January 29, 2016 | Volume: 15 | Issue: 3 | Pages: 523-530

10.1158/1535-7163.mct-15-0459 | PMID 26823492 Get It

Abstract Picornaviruses have emerged as promising cancer therapies due to their ability to drive cytotoxic cellular immune responses and for promoting oncolysis. These properties include preferential replication in tumor cells, the induction of strong innate and adaptive immune responses, and the ease with which their genomes can be manipulated. We have developed Theiler's murine encephalomyelitis virus (TMEV) as an immunotherapy vector that promotes strong adaptive immune responses to tumor antigens embedded within its genome. To further explore its usefulness as cancer therapy, we investigated whether direct intratumoral delivery of TMEV could promote tumor regression. We generated several picornavirus hybrids using substrains of TMEV that have unique immunopathologic characteristics, despite their extensive sequence homology. These hybrids exhibit a unique propensity to infect and replicate in melanoma. We have identified GD7-KS1, a virus that is particularly effective at replicating and infecting B16 melanoma in vitro and provides benefit as an oncolytic therapy in vivo after intratumoral injection. In addition, this virus promotes the mobilization and accumulation of CD8+ T cells within treated tumors. Altogether, these findings demonstrate that picornavirus substrains can be used to rationally design virus hybrids that promote antitumor responses and add to the known strategies identified by us and others to further enhance the therapeutic potential of vectors used to treat cancer. Mol Cancer Ther; 15(3); 523–30. ©2016 AACR.
Early Psychological Therapy in Critical Illness
Philbrick, Kemuel L. , Parker, Ann M. , Needham, Dale M. , Karnatovskaia, Lioudmila V.

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 136-142

10.1055/s-0035-1570367 | PMID 26820280 Get It

Controversies and Evolving Concepts in Critical Care
Cartin‐Ceba, Rodrigo , Pannu, Sonal , Gajic, Ognjen

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 001-002

10.1055/s-0035-1570360 | PMID 26820268 Get It

How Cool It Is: Targeted Temperature Management for Brain Protection Post–Cardiac Arrest
Rabinstein, Alejandro A.

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 034-041

10.1055/s-0035-1570357 | PMID 26820272 Get It

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease
Heyer, Christina M., Sundsbak, Jamie L., Chapman, Arlene B., Torres, Vicente E. , Grantham, Jared J. , Bae, Kyongtae T., Schrier, Robert W., Braun, William E. , Steinman, Theodore I., Mrug, Michal , Brosnahan, Godela , Irazabal, María V. , Flessner, Michael F., Moore, Charity G., Landsittel, Douglas , Harris, Peter C. , Investigators, for the HALT PKD and CRISP, Patterson, Charity G. , Hopp, Katharina , Abebe, Kaleab Z , Perrone, Ronald D. , Yu, Alan S.L. , Bennett, William M. , Investigators, for the HALT PKD and CRISP, Harris, Peter C , Torres, Vicente E , Irazabal, Maria V

Journal of the American Society of Nephrology | January 28, 2016 | Volume: 27 | Issue: 9 | Pages: 2872-2884

10.1681/asn.2015050583 | PMID 26823553 Get It

Autosomal dominant polycystic kidney disease (ADPKD) often results in ESRD but with a highly variable course. Mutations to PKD1 or PKD2 cause ADPKD; both loci have high levels of allelic heterogeneity. We evaluated genotype-phenotype correlations in 1119 patients (945 families) from the HALT Progression of PKD Study and the Consortium of Radiologic Imaging Study of PKD Study. The population was defined as: 77.7% PKD1, 14.7% PKD2, and 7.6% with no mutation detected (NMD). Phenotypic end points were sex, eGFR, height–adjusted total kidney volume (htTKV), and liver cyst volume. Analysis of the eGFR and htTKV measures showed that the PKD1 group had more severe disease than the PKD2 group, whereas the NMD group had a PKD2-like phenotype. In both the PKD1 and PKD2 populations, men had more severe renal disease, but women had larger liver cyst volumes. Compared with nontruncating PKD1 mutations, truncating PKD1 mutations associated with lower eGFR, but the mutation groups were not differentiated by htTKV. PKD1 nontruncating mutations were evaluated for conservation and chemical change and subdivided into strong (mutation strength group 2 [MSG2]) and weak (MSG3) mutation groups. Analysis of eGFR and htTKV measures showed that patients with MSG3 but not MSG2 mutations had significantly milder disease than patients with truncating cases (MSG1), an association especially evident in extreme decile populations. Overall, we have quantified the contribution of genic and PKD1 allelic effects and sex to the ADPKD phenotype. Intrafamilial correlation analysis showed that other factors shared by families influence htTKV, with these additional genetic/environmental factors significantly affecting the ADPKD phenotype.
GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression
Baumgart, Sandra, Chen, Nai-Ming, Zhang, Jin‐San , Billadeau, Daniel D. , Gaisina, Irina N. , Kozikowski, Alan P. , Singh, Shiv K. , Fink, Daniel , Klindt, Caroline , Bamlet, William R. , Köenig, Alexander , Heßmann, Elisabeth , Gress, Thomas M. , Ellenrieder, Volker , Neeße, Albrecht , Ströbel, Philipp , Zhang, Lizhi , Bamlet, William R , Singh, Shiv K

Molecular Cancer Therapeutics | January 28, 2016 | Volume: 15 | Issue: 3 | Pages: 491-502

10.1158/1535-7163.mct-15-0309 | PMID 26823495 Get It

Abstract We aimed to investigate the mechanistic, functional, and therapeutic role of glycogen synthase kinase 3β (GSK-3β) in the regulation and activation of the proinflammatory oncogenic transcription factor nuclear factor of activated T cells (NFATc2) in pancreatic cancer. IHC, qPCR, immunoblotting, immunofluorescence microscopy, and proliferation assays were used to analyze mouse and human tissues and cell lines. Protein–protein interactions and promoter regulation were analyzed by coimmunoprecipitation, DNA pulldown, reporter, and ChIP assays. Preclinical assays were performed using a variety of pancreatic cancer cells lines, xenografts, and a genetically engineered mouse model (GEMM). GSK-3β–dependent SP2 phosphorylation mediates NFATc2 protein stability in the nucleus of pancreatic cancer cells stimulating pancreatic cancer growth. In addition to protein stabilization, GSK-3β also maintains NFATc2 activation through a distinct mechanism involving stabilization of NFATc2–STAT3 complexes independent of SP2 phosphorylation. For NFATc2–STAT3 complex formation, GSK-3β–mediated phosphorylation of STAT3 at Y705 is required to stimulate euchromatin formation of NFAT target promoters, such as cyclin-dependent kinase-6, which promotes tumor growth. Finally, preclinical experiments suggest that targeting the NFATc2–STAT3–GSK-3β module inhibits proliferation and tumor growth and interferes with inflammation-induced pancreatic cancer progression in KrasG12D mice. In conclusion, we describe a novel mechanism by which GSK-3β fine-tunes NFATc2 and STAT3 transcriptional networks to integrate upstream signaling events that govern pancreatic cancer progression and growth. Furthermore, the therapeutic potential of GSK-3β is demonstrated for the first time in a relevant Kras and inflammation-induced GEMM for pancreatic cancer. Mol Cancer Ther; 15(3); 491–502. ©2016 AACR.
Spinal arteriovenous fistulae in patients with hereditary hemorrhagic telangiectasia: A case report and systematic review of the literature
Brinjikji, Waleed , Nasr, Deena M. , Cloft, Harry J. , Iyer, Vivek , Lanzino, Giuseppe

Interventional Neuroradiology | January 28, 2016 | Volume: 22 | Issue: 3 | Pages: 354-361

10.1177/1591019915623560 | PMID 26823330 Get It

Background Although rare, spinal arteriovenous malformations (AVMs) are thought to be more prevalent in the hereditary Hereditary Hemorrhagic Telangiectasia (HHT) population. Methods We report a case of a spinal AVM in a 37-year-old female with HHT treated with endovascular embolization. In addition, we report findings from a systematic review of the literature on the clinical characteristics, angioarchitecture, and clinical outcomes of HHT patients with spinal AVMs. Results The patient is a 37 year-old female with definite HHT who presented with a one-year history of progressive gait difficulty. The spinal fistula was incidentally detected on chest computed tomography (CT). Spinal angiography demonstrated a large perimedullary arteriovenous fistula was supplied by a posterolateral spinal artery. The fistula was treated with detachable coils. The patient made a complete neurological recovery. Our systematic review yielded 25 additional cases of spinal AVMs in HHT patients. All fistulae were perimedullary (100.0%). Treatments were described in 24 of the 26 lesions. Endovascular-only treatment was performed in 16 cases (66.6%) and surgical-only treatment was performed in five cases (20.8%). Complete or near-complete occlusion rates were 86.7% (13/15) for endovascular treated cases, 100.0% (4/4) for surgery and 66.6% (2/3) for combined treatments. Overall, 80.0% of patients (16/20) reported improvement in function following treatment, 100.0% (5/5) in the surgery group and 84.6% (11/13) reported improvement in the endovascular group. Conclusions Spinal fistulae in HHT patients are usually type IV perimedullary fistulae. Both endovascular and surgical treatments appeared to be effective in treating these lesions. However, it is clear that endovascular therapy has become the preferred treatment modality.
Can endosheath technology open primary care doors to Barrett’s esophagus screening by transnasal endoscopy?
Iyer, Prasad G. , Chak, Amitabh

Endoscopy | January 28, 2016 | Volume: 48 | Issue: 02 | Pages: 105-106

10.1055/s-0034-1393561 | PMID 26820077 Get It

Balance between Hyperinflammation and Immunosuppression in Sepsis
Yadav, Hemang , Cartin‐Ceba, Rodrigo

Seminars in Respiratory and Critical Care Medicine | January 28, 2016 | Volume: 37 | Issue: 01 | Pages: 042-050

10.1055/s-0035-1570356 | PMID 26820273 Get It